R&D key to pharma sector: Harney

Europe faces paying a heavy price if the continued fall-off in R&D investment by the pharmaceutical industry within the European Union is allowed to continue unchecked, the Tánaiste Mary Harney said today.

R&D key to pharma sector: Harney

Europe faces paying a heavy price if the continued fall-off in R&D investment by the pharmaceutical industry within the European Union is allowed to continue unchecked, the Tánaiste Mary Harney said today.

Job losses and reduced economic activity will be the end result, she added.

Already a subscriber? Sign in

You have reached your article limit.

Subscribe to access all of the Irish Examiner.

Annual €130 €80

Best value

Monthly €12€6 / month

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited